New combo therapy aims to shrink deadly esophageal tumors
NCT ID NCT06531434
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This pilot study tests a two-step treatment for T4 esophageal cancer, where the tumor has spread to nearby organs. First, patients receive up to 8 cycles of chemotherapy with docetaxel, cisplatin, and fluorouracil. If the tumor shrinks enough, they then get a lower dose of radiation combined with cisplatin. The goal is to see if this approach reduces the risk of a hole forming in the esophagus (perforation) and improves response and survival. The study enrolls 22 adults aged 18-70 with good organ function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Docetaxel, Cisplatin, fluorouracil, and radiation
What this could lead to
If successful, this approach could offer a safer and more effective treatment strategy for advanced esophageal cancer, potentially improving survival and reducing complications.
What could go wrong
This is a small, early-phase pilot study with only 22 participants, so results may not apply broadly. The treatment involves strong chemotherapy and radiation, which carry risks like infection, bleeding, and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER TNM STAGING PRIMARY TUMOR (T) T4 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cheng Kung University Hospital
RECRUITINGTainan, Taiwan, 704302, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••